Shooting for the Moon

The Cancer Moonshot Initiative seeks to end cancer as we know it, but is the moonshot a long shot?

Learn more

Recommendations from My Bookshelf

"Have you ever been a stranger in a strange land?" Mikkael Sekeres, MD, MS, reviews Cutting for Stone by Abraham Verghese.

Learn more

What to Call What We Treat (Part 2)

In Written in Blood, we review the World Health Organization's recent updates to the classification of myeloid neoplasms and acute leuk

Learn more

Pulling Back the Curtain

Robert P. Gale, MD, PhD (pictured here taking a sand bath), talks about his varied career and atomic hematology.

Learn more

On Location

At this year's American Association for Cancer Research Annual Meeting, scientists and physicians discuss the future of personalized th

Learn more
Advertisement

Exclusive Videos

View all Exclusive Videos

  • Recommendations from My Bookshelf: Cutting for Stone by Abraham Verghese

    Have you ever been a stranger in a strange land? I thought I was when I moved from New England to Cleveland, where I had to learn to talk a little slower, and that unfamiliar people who smiled and said “hi” as they passed me in the hallways were not mentally unstable – as I […]

  • Kindred Spirits

    “Kindred spirits are not so scarce as I used to think. It’s splendid to find out there are so many of them in the world.” ― L.M. Montgomery, Anne of Green Gables Despite the cultural and political differences that divide us, humans across the globe are remarkably similar. As Sting once sang, “We share the […]

  • Why Did You Become a Hematologist?

    I am truly curious as to why doctors in training choose a career in hematology, particularly malignant hematology. My ASH Clinical News editorial colleague, David Steensma, MD, said he was hooked after witnessing the beauty of an eosinophil under a microscope as a first-year medical student. For me, it was my fascination at the seemingly […]

  • Letter From a Cleveland Jail to the ABIM: MOC Madness

    American Board of Internal Medicine Philadelphia, PA March 2016 Dear ABIM, Got your last email. Are you just not that into me anymore? There it sat, an unsightly wart amidst the usual compelling missives occupying my Outlook inbox, with the subject header: “Important update about your certification status.” I opened the message immediately, because you […]

View all Editor`s Corner
  • Optimal Timing of Transplant in Myeloma

    New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront stem cell transplantation. ASH Clinical News has invited Shaji Kumar, MD, and Ola Landgren, MD, to debate the question: “What is the optimal timing for hematopoietic cell transplantation in patients with […]

  • Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

    Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these devices is unclear. The potential complications associated with filter placement and retrieval may outweigh the benefit, particularly in the era of novel oral anticoagulants. ASH Clinical News invited Joseph M. Stavas, […]

  • For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

    Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen for treating acute thrombotic events in these patients, questions remain about its optimal use, including the duration of anticoagulation. ASH Clinical News invited David A. Garcia, MD, and Agnes Y. Lee, […]

  • Is Fludarabine Dead in CLL?

    A few short years ago, fludarabine was considered the gold standard of front-line treatment for chronic lymphocytic leukemia (CLL), providing better response rates than old standby, chlorambucil. Now, in an era of monoclonal antibodies and targeted therapies, fludarabine is losing its place as leader of the pack. ASH Clinical News has invited Steven Coutre, MD, […]

View all Drawing First Blood
  • CMS Tests New Medicare Part B Reimbursement Model: How Will It Affect Hematologists?

    In March, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule to test new models to improve Medicare Part B physician reimbursements for prescription drugs.1 According to CMS, the rule will test different physician incentives that would, in theory, encourage the prescription of the most effective drugs and reward positive patient outcomes. […]

  • Choosing Wisely Across the Internal Medicine Spectrum: Which Recommendations Should Hematologists Pay Attention To?

    In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASH released a list of hematology-related tests and procedures to question based on recommendations from other medical societies at the 2015 annual meeting. Choosing Wisely encourages clinicians and patients to engage in conversations to reduce waste and overuse in health care. […]

  • New Medicare Care Choices Model Seeks to Expand Access to Palliative Care

    On July 20, 2015, the Centers for Medicare& Medicaid Services (CMS) announcedthe 141 hospices that have been selected to participate in the new Medicare Care Choices Model (MCCM), a pilot program designed to expand patients’ access to palliative and hospice care.1 The new model provides clinicians, beneficiaries, and their families with greater flexibility in deciding between hospice care and active […]

  • ICD-10: Ready or Not!

    After two one-year reprieves, it’s finally here: The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Nationwide, on October 1, 2015, all health-care business transactions in the United States converted to ICD-10 from the previous version of the ICD (ICD-9). If they did not convert, claims and electronic transactions will be rejected. The ICD-9 […]

View all Practice Update